Table 1.
Patients included in the study
|
RAS WT |
RAS MT |
KRAS G12 |
KRAS G13 |
RAS other | Total (overall cohort) | KRAS WT versus KRASMT (P value) | Overall cohort:G12 versus noG12 (P value) | RAS MT cohort:G12 versus noG12 (P value) | KRAS exon 2 cohort:G12 versus noG12 (P value) | |
|---|---|---|---|---|---|---|---|---|---|---|
| N (%) | 47 (38.2%) | 76 (61.8%) | 51 (41.5%) | 8 (6.5%) | 25 (20.3%) | 123 (100.0%) | ||||
| Age, years [95% IQR] | 64.3 [60.49-68.92] | 65.5 [62.64-68.64] | 66.1 [59.45-71.08] | 64.8 [58.78-72.31] | 64.8 [59.48-69.33] | 65.2 [62.73-68.05] | 0.909 | 0.796 | 0.807 | 0.959 |
| <65 | 24 (51.1%) | 38 (50.0%) | 25 (49.0%) | 4 (50.0%) | 13 (52.0%) | 59 (50.4%) | ||||
| ≥65 | 23 (48.9%) | 38 (50.0%) | 26 (51.0%) | 4 (50.0%) | 12 (48.0%) | 58 (49.6%) | ||||
| Sex | ||||||||||
| M | 30 (63.8%) | 45 (59.2%) | 28 (54.9%) | 6 (75.0%) | 17 (68.0%) | 71 (60.7%) | 0.610 | 0.245 | 0.275 | 0.285 |
| F | 17 (36.2%) | 31 (40.8%) | 23 (45.1%) | 2 (25.0%) | 8 (32.0%) | 46 (39.3%) | ||||
| Left primary site | 36 (76.6%) | 55 (72.4%) | 37 (72.5%) | 5 (62.5%) | 18 (72.0%) | 91 (74.0%) | 0.604 | 0.760 | 0.960 | 0.560 |
| Surgery in curative intention | 30 (63.8%) | 43 (56.6%) | 32 (62.7%) | 1 (12.5%) | 11 (44.0%) | 73 (59.3%) | 0.426 | 0.519 | 0.121 | 0.008 |
| Prior lines | ||||||||||
| 0-1 | 5 (10.6%) | 20 (26.3%) | 14 (27.5%) | 2 (25.0%) | 6 (24.0%) | 25 (20.3%) | 0.036 | 0.098 | 0.748 | 0.885 |
| 2 | 24 (51.1%) | 42 (55.3%) | 28 (54.9%) | 6 (75.0%) | 14 (56.0%) | 66 (53.7%) | 0.650 | 0.816 | 0.928 | 0.285 |
| 3 or more | 18 (38.3%) | 14 (18.4%) | 9 (17.6%) | 0 (0.0%) | 5 (20.0%) | 32 (26.0%) | 0.015 | 0.075 | 0.804 | 0.197 |
| Refractory to 5-FU | 25 (53.2%) | 45 (59.2%) | 31 (60.8%) | 5 (62.5%) | 14 (56.0%) | 70 (56.9%) | 0.512 | 0.465 | 0.690 | 0.926 |
| Prior bevacizumab | 34 (72.3%) | 68 (89.5%) | 47 (92.2%) | 8 (100.0%) | 21 (84.0%) | 102 (82.9%) | 0.014 | 0.022 | 0.276 | 0.412 |
| Meta-time <18 month | 17 (36.2%) | 35 (46.1%) | 22 (43.1%) | 4 (50.0%) | 13 (52.0%) | 52 (42.3%) | 0.281 | 0.871 | 0.466 | 0.716 |
| ECOG | ||||||||||
| 0-1 | 40 (85.1%) | 68 (89.5%) | 47 (92.2%) | 7 (87.5%) | 21 (84.0%) | 108 (87.8%) | 0.472 | 0.214 | 0.276 | 0.660 |
| Number of metastatic sites | ||||||||||
| 1-2 | 38 (80.9%) | 51 (67.1%) | 33 (64.7%) | 4 (50.0%) | 18 (72.0%) | 89 (72.4%) | 0.098 | 0.110 | 0.525 | 0.424 |
| Peritoneal involvement | 11 (23.4%) | 21 (27.6%) | 11 (21.6%) | 4 (50.0%) | 10 (40.0%) | 32 (26.0%) | 0.604 | 0.344 | 0.091 | 0.086 |
| Lung only disease | 4 (8.5%) | 8 (10.5%) | 7 (13.7%) | 1 (12.5%) | 1 (4.0%) | 12 (9.8%) | 0.714 | 0.212 | 0.194 | 0.925 |
| Local therapy | 10 (21.3%) | 9 (11.8%) | 4 (7.8%) | 0 (0.0%) | 5 (20.0%) | 19 (15.4%) | 0.159 | 0.050 | 0.123 | 0.412 |
| Further systemic therapy | 18 (38.3%) | 30 (39.5%) | 22 (43.1%) | 2 (25.0%) | 8 (32.0%) | 48 (39.0%) | 0.897 | 0.431 | 0.351 | 0.332 |
| Prior irinotecan | 43 (91.5%) | 59 (77.6%) | 40 (78.4%) | 6 (75.0%) | 19 (76.0%) | 102 (82.9%) | 0.047 | 0.265 | 0.811 | 0.828 |
| Prior oxaliplatin | 44 (93.6%) | 58 (76.3%) | 40 (78.4%) | 6 (75.0%) | 18 (72.0%) | 102 (82.9%) | 0.013 | 0.265 | 0.536 | 0.828 |
| Best overall response | ||||||||||
| CR | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0.515 | 0.99 | 0.851 | 0.99 |
| PR | 2 (4.5%) | 5 (7.1%) | 3 (6.4%) | 0 (0%) | 2 (8.7%) | 7 (6.1%) | ||||
| SD | 16 (36.4%) | 28 (40%) | 18 (38.3%) | 3 (37.5%) | 10 (43.5%) | 44 (38.6%) | ||||
| DCR | 18 (40.9%) | 33 (47.1%) | 21 (44.7%) | 3 (37.5%) | 12 (52.2%) | 51 (44.7%) | ||||
| PD | 26 (59.1%) | 37 (52.9%) | 26 (55.3%) | 5 (62.5%) | 11 (47.8%) | 63 (55.3%) | ||||
| NA | 3 (6.4%) | 6 (7.9%) | 4 (7.8%) | 0 (0%) | 2 (8%) | 9 (7.3%) |
5-FU, 5-fluorouracil; CR, complete response; DCR (CR+PR+SD), disease control rate; ECOG, Eastern Cooperative Oncology Group; meta-time, time since diagnosis of first metastases; MT, mutant; NA, not available; PD, progressive disease; PR, partial response; SD, stable disease; WT, wild type.